Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biogen Idec
(NQ:
BIIB
)
221.50
-1.25 (-0.56%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
37
38
Next >
Why I Sold My Biogen Stock
August 05, 2021
It has everything to do with Aduhelm.
Via
The Motley Fool
Analyst Ratings for Biogen
August 02, 2021
Biogen (NASDAQ:BIIB) has observed the following analyst ratings within the...
Via
Benzinga
Will Biogen Be Able to Move Past the Drama Surrounding Its Alzheimer's Disease Drug?
July 31, 2021
Probably.
Via
The Motley Fool
Topics
Cannabis
Exposures
Cannabis
Is Now a Good Time to Buy Biogen Stock?
July 30, 2021
It's a definite maybe.
Via
The Motley Fool
Topics
Cannabis
Exposures
Cannabis
Why Biogen's Stock Has Likely Peaked
July 30, 2021
The stock has a tough road back to $400, assuming it can get back there at all.
Via
The Motley Fool
Annovis Bio Shares Cut In Half Following Alzheimer's Data Presentation
July 29, 2021
Annovis Bio, Inc. (NYSE: ANVS), which took off on a strong rally in January, has quickly lost most of the gains. What To Know: Annovis, a clinical-stage neurodegenerative diseases...
Via
Benzinga
Expert Ratings For Biogen
July 23, 2021
Within the last quarter, Biogen (NASDAQ:BIIB) has observe...
Via
Benzinga
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs
July 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
Product Safety
Annovis Bio Stock Crashes After Much-Hyped Alzheimer's Drug Flops In Midstage Test
July 29, 2021
Annovis Bio's Alzheimer's drug failed to significantly outperform the placebo in a midstage test, leading ANVS stock to plummet on Thursday.
Via
Investor's Business Daily
Should You Invest in This Seemingly Unstoppable Alzheimer's Biotech?
July 29, 2021
This popular life science company has a fair but risky shot of developing a novel drug to treat Alzheimer's disease.
Via
The Motley Fool
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
July 29, 2021
FDA approval of roxadustat seems unlikely.
Via
The Motley Fool
Topics
Cannabis
Exposures
Cannabis
Product Safety
After Aduhelm Win, Biogen Touts Encouraging Data From Second Alzheimer's Candidate
July 27, 2021
Biogen Inc (NASDAQ: BIIB) and Ionis Pharmaceuticals Inc (NASDAQ: IONS) have announced topline data from a Phase 1b study of BIIB080/IONIS-MAPTRx in mild...
Via
Benzinga
Analysis Shows Biogen-Eisai's Aduhelm Slows Cognitive, Functional Decline In Early Alzheimer's Patients
July 27, 2021
An analysis of Phase 3 data presented by Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) of its Alzheimer's therapy Aduhelm (aducanumab) ...
Via
Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs, And More
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefited from the optimism that was set in motion by the solid start to the pharma reporting...
Via
Talk Markets
Exposures
Product Safety
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
July 25, 2021
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...
Via
Benzinga
Exposures
Product Safety
Could These 3 Potential Blockbusters Transform Biogen?
July 25, 2021
The company is moving into three billion-dollar areas.
Via
The Motley Fool
Why Annovis Stock Is Bucking The Trend In Alzheimer's — And Two Others To Watch
July 23, 2021
Annovis bucked the trend depressing Alzheimer's stocks on Friday as ANVS stock touched a record high while SAVA stock and INMB stock fell.
Via
Investor's Business Daily
Stock Market Rally Rebounds To Highs; Snap, Crocs, Chipotle, Netflix Are Key Earnings
July 23, 2021
The market rally rebounded from Monday, with the S&P 500 hitting a record high. Snap, Crocs, Chipotle were earnings winners
Via
Investor's Business Daily
Topics
Earnings
Stocks
Exposures
Financial
Fossil Fuels
US Equities
Investors Too Gloomy Over Biogen Alzheimer’s Drug
July 23, 2021
There are good reasons to be skeptical that Biogen’s Aduhelm, the first new treatment for Alzheimer’s disease in nearly two decades, will change patients’ lives for the better.
Via
Talk Markets
Biogen inc (BIIB) Q2 2021 Earnings Call Transcript
July 22, 2021
BIIB earnings call for the period ending June 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Cassava Sciences Stock Soars In Anticipation Of Alzheimer's Data: A Technical Analysis
July 22, 2021
On Thursday, Cassava Sciences, Inc (NASDAQ: SAVA) smashed through a resistance level at $117.54, made 21 years ago between its initial public offering date of June 14,...
Via
Benzinga
IGC Stock: The Huge Cannabis Patent News That Has IGC Flying High
July 22, 2021
IGC stock is moving up in a huge way today. The company is finally earning its patent for the treatment of Alzheimer's disease with cannabis.
Via
InvestorPlace
Topics
Cannabis
Intellectual Property
Exposures
Cannabis
Intellectual Property
Product Safety
Biogen's Q2 Profit Falls 70% As Tecfidera Competition Hits Topline
July 22, 2021
Biogen Inc posted Q2 adjusted EPS of $5.68 ahead of the consensus estimate of $4.55, but quarterly profit fell around 71% Y/Y to $448.5 million as competition intensified for the Company's flagship...
Via
Talk Markets
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
July 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical...
Via
Benzinga
Exposures
Product Safety
Biogen: Q2 Earnings Insights
July 22, 2021
Shares of Biogen (NASDAQ:BIIB) fell 0.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 44.64% over the past year to...
Via
Benzinga
Biogen's Q2 Profit Falls 70% As Tecfidera Competition Hits Topline
July 22, 2021
Biogen Inc (NASDAQ: BIIB) posted Q2 adjusted EPS of $5.68 ahead of the consensus estimate of $4.55, but quarterly profit fell around 71% Y/Y to $448.5 million as...
Via
Benzinga
Biogen Earnings, Sales Top Q2 Views; Stock Rises
July 22, 2021
Biogen earnings and sales fell, but beat Q2 views. Biogen stock rose slightly.
Via
Investor's Business Daily
Here's Why Cassava Sciences Is Surging Today
July 21, 2021
Investors are excited about upcoming presentations scheduled for the annual Alzheimer's Association International Conference.
Via
The Motley Fool
Exposures
Product Safety
SAVA Stock: Two Dates Cassava Investors Need to Mark on Their Calendars
July 21, 2021
SAVA stock is flying upward today as investors clamor to hear information around two new products. Investors should save two upcoming dates.
Via
InvestorPlace
Earnings Scheduled For July 22, 2021
July 22, 2021
Companies Reporting Before The Bell • Champions Oncology, Inc. - Common Stock (NASDAQ:CSBR) is estimated to report earnings for its fourth quarter. • MarineMax,...
Via
Benzinga
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.